Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

8,743 38,240 46,983

Oncology 23,949 47,642 71,591 8,743 38,240 46,983

Other 26,644 82,517 109,161 25,833 75,863 101,696

$727,480 $191,459 $918,939 $696,685 $162,388 $859,073

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 7% 26% 8%

GABITRIL (5%) (20%) (8%)

CNS 6% 18% 7%

ACTIQ (32%) 41% (21%)

Generic OTFC (13%) - (13%)

FENTORA 11% - 11%

AMRIX 100% - 100%

Pain (4%) 41% (1%)

TREANDA 100% - 100%

Other 9% 25% 22%

Oncology 174% 25% 52%

Other 3% 9% 7%

4% 18% 7%

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

June 30, December 31,

2008 2007

CURRENT ASSETS:

<
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... Beike,Biotechnology Co., Ltd. ( http://www.beikebiotech.com ), ... stem cells to successfully treat a variety of,illnesses, ... of,Manchester, has returned today to the United Kingdom ... condition known as,cerebellar atrophy. As the latest of ...
... BioSpace, the world,s leading,niche online bioscience career ... its reach to local regional candidates through ... onTargetjobs. With the,inclusion of RegionalHelpWanted.com,s network of ... now offers biotechnology,pharmaceutical, medical device and academic ...
... Feb. 14 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... specialty pharmaceutical and,medical device company, today announced ... the fourth quarter and year ended,December 31, ... to further,review and potential adjustment as described ...
Cached Biology Technology:Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 2Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 3BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition 2BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition 3Angiotech announces results for the fourth quarter ended December 31, 2007 2Angiotech announces results for the fourth quarter ended December 31, 2007 3Angiotech announces results for the fourth quarter ended December 31, 2007 4Angiotech announces results for the fourth quarter ended December 31, 2007 5Angiotech announces results for the fourth quarter ended December 31, 2007 6Angiotech announces results for the fourth quarter ended December 31, 2007 7Angiotech announces results for the fourth quarter ended December 31, 2007 8Angiotech announces results for the fourth quarter ended December 31, 2007 9Angiotech announces results for the fourth quarter ended December 31, 2007 10Angiotech announces results for the fourth quarter ended December 31, 2007 11Angiotech announces results for the fourth quarter ended December 31, 2007 12Angiotech announces results for the fourth quarter ended December 31, 2007 13Angiotech announces results for the fourth quarter ended December 31, 2007 14Angiotech announces results for the fourth quarter ended December 31, 2007 15Angiotech announces results for the fourth quarter ended December 31, 2007 16Angiotech announces results for the fourth quarter ended December 31, 2007 17Angiotech announces results for the fourth quarter ended December 31, 2007 18Angiotech announces results for the fourth quarter ended December 31, 2007 19Angiotech announces results for the fourth quarter ended December 31, 2007 20Angiotech announces results for the fourth quarter ended December 31, 2007 21Angiotech announces results for the fourth quarter ended December 31, 2007 22Angiotech announces results for the fourth quarter ended December 31, 2007 23Angiotech announces results for the fourth quarter ended December 31, 2007 24
(Date:9/18/2014)... McGill University and the Quebec government have discovered ... Canadian Journal of Fisheries and Aquatic Sciences . ... cleansers, or industrial cleansers, to which they are ... size and buoyancy, they may readily pass through ... contaminant in the world,s oceans, but have only ...
(Date:9/18/2014)... and creatively manipulate spoken language is unique to humans. ... million years of human evolution to make this possible ... gene we now have," says Wolfgang Enard, Professor of ... to understand the molecular biological basis of language Enard ... of his latest study, undertaken in collaboration with scientists ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... RNA molecules, previously thought to have no function, may in ... published in the November 17 issue of the journal Cell. ... of gene expression. When a gene is ready to produce ... gene unravel. The first strand produces a molecule called messenger ...
... international team of researchers has shed new light on ... generate the energy that powers their movements. , The ... mechanisms of a range of human disorders such as ... to the development of new treatments, the researchers said. ...
... passed from parents to offspring via sperm or eggs, also ... the genes can be passed to the next generation in ... the genetic material after it has been duplicated and then ... or spores. Near the end of the process, the material ...
Cached Biology News:Scientists discover role for dueling RNAs 2Researchers image molecular motor structural changes 2Researchers image molecular motor structural changes 3Researchers image molecular motor structural changes 4Single molecular 'mark' seen as pivotal for genome compaction in spores and sperm 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
... FbxL7 The F box, named ... was originally observed, is an approximately ... F-box proteins are components of modular ... (SKP1, cullin, F-box proteins), which function ...
Biology Products: